Neuromodulation Focused Company Axonics Gets 28% Price Target Bump By This Analyst On Solid Q2 Performance

  • Axonics Inc AXNX reported a 50% Y/Y increase in Q2 sales to $69 million, beating the consensus of $59 million.
  • Sacral neuromodulation (SNM) revenue was $55.8 million, and Bulkamid revenue was $13.2 million.
  • The company reported an EPS loss of $(0.47), better than $(0.59) a year ago and the consensus of $(0.54).
  • Needham has raised the price target to $77 from $60 with an unchanged Buy rating, citing that stronger revenue growth warrants a higher EV/sales multiple.
  • The analyst says that the 2Q22 results support the view that AXNX's non-rechargeable F15 system is helping to drive market share gains for AXNX.
  • The company forecasts FY22 sales of $253 million, +40% Y/Y, and better than the previous guidance of $238 million.
  • Sacral neuromodulation revenue is expected to reach $205 million, +30%, with Bulkamid revenue to more than double to $48 million.
  • Axonics launched its F15 non-rechargeable SNM system in April this year after gaining FDA approval in March.
  • Management noted that ~66% of its 2Q22 sales were from the F15 though management expects this to shift back toward ~50% over time. 
  • Needham notes that F15 has nearly twice the battery life of Medtronic Plc's MDT new Interstim X non-rechargeable system, along with other advantages. 
  • Price Action: AXNX shares are up 4.74% at $69.82 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CarePrice TargetAnalyst RatingsMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!